ISPE Issues Guidance for Packaging, Labeling, and Warehousing Facilities

News
Article

ISPE has issued a guidance that is intended to help companies meet cGMP requirements for packaging, labeling, and warehousing facilities and avoid problems such as product adulteration, product mix-up, label mix-up, and misbranding.

The International Society of Pharmaceutical Engineering (ISPE) released guidance for the design, construction, and commissioning and qualification of packaging, labeling, and warehousing (PACLAW) facilities.  The ISPE Good Practice Guide: Packaging, Labeling, and Warehousing Facilities helps companies meet cGMP requirements for PACLAW facilities and avoid problems such as product adulteration, product mix-up, label mix-up, and misbranding.

“PACLAW facilities are very different from other types of pharmaceutical facilities, and up until this point, there has been no consistent guidance available to help companies ensure compliance,” said guide author Nick Davies in a July 3, 2012 press release. “With this ISPE guide, the industry finally has tools to ensure their PACLAW processes are efficient, compare their processes to established best practices, and demonstrate compliance to regulatory agencies.”

The guide gives direction on designing or reconfiguring PACLAW facilities using quality-by-design principles. It also explains how PACLAW facilities can comply with FDA’s systems-based approach, which uses a risk-based inspection model.

Recent Videos
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.